Revenue (Tables)

9 Months Ended

Jun. 30, 2024

Revenue from Contract with Customer [Abstract]

Summary of Disaggregation of Revenue Within Reportable Segment

The following table is a disaggregation of revenue within each reportable segment.

	Three Months Ended June 30,				Nine Months Ended June 30,
(In thousands)	2024		2023		2024		2023
Medical Device
Product sales	$	10,726	$	9,299	$	33,776	$	25,593
Royalties & license fees – performance coatings		9,324		8,286		27,855		23,853
License fees – SurVeil DCB		1,134		25,867		3,193		28,494
Research, development and other		2,199		2,562		6,930		6,799
Medical Device Revenue		23,383		46,014		71,754		84,739
In Vitro Diagnostics
Product sales		6,836		6,368		20,712		19,658
Research, development and other		122		101		385		217
In Vitro Diagnostics Revenue		6,958		6,469		21,097		19,875
Total Revenue	$	30,341	$	52,483	$	92,851	$	104,614